Organon(OGN.US)因内部控制问题重挫，再遭Piper Sandler大砍目标价至5美元

Core Viewpoint - Piper Sandler downgraded Organon (OGN.US) from "Overweight" to "Underweight" and reduced the target price from $18 to $5 due to significant internal control deficiencies revealed during an audit committee investigation, affecting financial statements for 2022, 2024, and 2025 [1] Company Summary - The downgrade indicates a long recovery path for Organon, primarily due to the need to restore internal controls and investor confidence [1] - Following the downgrade, Organon's stock price fell approximately 23% [1] - Analysts caution that the current uncertainty and the company's journey to profitability will be lengthy and challenging, potentially increasing risk and volatility [1]